Last $110.58 USD
Change Today -1.22 / -1.09%
Volume 516.0K
BCR On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 4:15 PM 06/19/13 All times are local (Market data is delayed by at least 15 minutes).

cr bard inc (BCR) Snapshot

Open
$111.77
Previous Close
$111.80
Day High
$112.36
Day Low
$110.41
52 Week High
06/19/13 - $112.36
52 Week Low
08/2/12 - $93.69
Market Cap
8.9B
Average Volume 10 Days
639.3K
EPS TTM
$6.41
Shares Outstanding
80.5M
EX-Date
07/18/13
P/E TM
17.3x
Dividend
$0.84
Dividend Yield
0.72%
Current Stock Chart for CR BARD INC (BCR)

Related News

No related news articles were found.

cr bard inc (BCR) Related Businessweek News

No Related Businessweek News Found

cr bard inc (BCR) Details

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusions catheters, guidewires, fabrics, meshes, introducers, and accessories; peripheral vascular stents, covered stents, and vascular grafts; vena cava filters; biopsy devices; electrophysiology products; and drug coated balloon devices to treat peripheral vascular disease and heart arrhythmias. Its urology products comprise Foley catheters to reduce the rate of urinary tract infections; surgical slings to treat stress urinary incontinence; fecal incontinence products; natural and synthetic devices to treat pelvic floor and vaginal prolapse; brachytherapy services, devices, and radioactive seeds to treat prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal; catheter stabilization devices; and products for therapeutic hypothermia. The company also provides oncology products, such as specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders. Its surgical specialty products include soft tissue repair products, such as hernia repair grafts and hernia fixation devices; surgical sealants for intraoperative sealing of air leaks in thoracic surgery; and other products, such as irrigation, wound drainage, and original equipment manufacturers’ products. The company sells its products to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities directly, as well as through hospital/surgical supply and other medical specialty distributors. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey.

12,200 Employees
Last Reported Date: 02/20/13
Founded in 1907

cr bard inc (BCR) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.1M
President, Chief Operating Officer and Direct...
Total Annual Compensation: $887.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $407.3K
Group Vice President
Total Annual Compensation: $537.5K
Group Vice President
Total Annual Compensation: $537.5K
Compensation as of Fiscal Year 2012.

cr bard inc (BCR) Key Developments

CR Bard Inc. Increases Quarterly Dividend, Payable on August 2, 2013

The Board of Directors of CR Bard Inc. increased the quarterly dividend on Bard's common stock by 5%, to 21 cents per share. The dividend is payable on August 2, 2013 to shareholders of record at the close of business on July 22, 2013.

Thousands of Transvaginal Mesh Lawsuit Claims File Against American Medical Systems, Inc., CR Bard Inc., Ethicon, Inc. and Boston Scientific Corp

Thousands of transvaginal mesh lawsuit claims filed against American Medical Systems, Inc., CR Bard Inc., Ethicon, Inc. and Boston Scientific Corp. continue to move forward in the federal litigations now underway in U.S. District Court, Southern District of West Virginia, Bernstein Liebhard LLP reports. According to a Pretrial Order dated May 29th, 2013, the Court recently issued revised Short Form and Amended Short Form Complaints, which must be used by parties filing new cases or amended complaints in the litigations as of June 5th, 2013. According to court records, the next joint Status Conference in the federal vaginal mesh litigations has been scheduled for August 1st, 2013.

CR Bard Inc. Pays $48.2 Million to Settle Whistleblower Lawsuit in Georgia

CR Bard Inc. has agreed to pay the federal government $48.2 million to settle a whistleblower lawsuit that alleges its urological division and wholly owned subsidiary, ProSeed Inc., paid doctors and hospitals kickbacks to entice them to order Bard's products at inflated prices to treat Medicare patients with prostate cancer. Bard and ProSeed, based in Covington, Georgia, sold radioactive seeds used for brachytherapy, a treatment for prostate cancer. The seeds are permanently implanted in the prostate to deliver a prescribed dose of radiation directly to the cancer cells. The qui tam lawsuit alleged that from 1998 to 2006 Bard inflated the costs of the seeds sold to treat Medicare patients, using a portion of its excess profits to pay for kickbacks. By paying kickbacks, Bard caused false and inflated claims to be submitted to Medicare, which is a violation of the False Claims Act.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCR:US $110.58 USD -1.22

BCR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $37.53 USD -0.54
Edwards Lifesciences Corp $68.82 USD -1.34
Getinge AB kr210.00 SEK -0.90
Sigma-Aldrich Corp $81.19 USD -0.99
Varian Medical Systems Inc $68.78 USD -2.08
View Industry Companies
 

Industry Analysis

BCR

Industry Average

Valuation BCR Industry Range
Price/Earnings 19.8x
Price/Sales 3.1x
Price/Book 4.7x
Price/Cash Flow 18.7x
TEV/Sales 2.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CR BARD INC, please visit www.crbard.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.